View Presentation Slides - PCSS-O

More documents

Recommendations

Info

Number Pain Location 79 80 70 60 50 40 30 20 10 17 13 7 0 Lower Back Pain Multiple Joint Arthritis Migraines Fibromyalgia
Adjuvant Medications Na and Interventions N = 143 Antidepressants # NSAIDS # Anticonvulsant s # M. Relaxers # Other # Amitriptyline 3 Celebrex 1 Gabapentin 31 Baclofen 11 Capsaicin 7 Duloxetine 5 Ibuprofen 25 Pregabalin 9 Cyclobenzaprine 7 ESI 3 Nortriptyline 1 Ketoprofen 1 Methocarb. 7 Lidocaine patch Paroxetine 6 Meloxicam 4 Tizanidine 2 Intra-art. injection Venlafaxine 18 Naproxen 8 TENS 10 Salsalate 1 Pain group 5 TOTALS 33 40 40 27 43 5 13
Page 1 and 2: Patricia Pade, MD University of Col
Page 3 and 4: Objectives • To provide a brief o
Page 5 and 6: Chronic Pain • 116 million people
Page 7 and 8: Opioid Use • Use of opioids has i
Page 9 and 10: Fatal Drug Poisoning • Between 19
Page 11 and 12: Opioid Pharmacology: How do these M
Page 13 and 14: • Tolerance: Repeated Dosing: Opi
Page 15 and 16: Brief pharmacology overview: full o
Page 17 and 18: Brief pharmacology overview: opioid
Page 19 and 20: The Use of Buprenorphine/Naloxone t
Page 21 and 22: The Problem for Veterans
Page 23 and 24: Improvement Change: Creation of Co-
Page 25 and 26: Patient population • Referrals fr
Page 27 and 28: Initial Evaluation A. PAIN Detailed
Page 29 and 30: Buprenorphine induction process •
Page 31 and 32: Study participants Participant Data
Page 33 and 34: Months Average duration of opioid u
Page 35: Number Number Number 60 40 Co-morbi
Page 39 and 40: Ongoing monitoring for compliance
Page 41 and 42: 93/143 patients remained in treatme
Page 43 and 44: Conclusions 11. Patients with co-oc
Page 45 and 46: Office Based Opioid Treatment: Bupr
Page 47: References 1. Institute of Medicine

View Presentation Slides - PCSS-O

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?